Unlocking New Avenues in Breast Cancer Treatment: The Synergy of Kinase Inhibitors and Immunotherapy

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2023 Dec 9

PMID 38067203

Authors

Maria Jose Bravo

Antonio Manuel Burgos-Molina

Marilina Garcia-Aranda

Maximino Redondo

Teresa Tellez

Affiliations

Soon will be listed here.

Abstract

Cancer is one of the world's most significant health problems today. Currently, breast cancer has globally surpassed lung cancer as the most commonly diagnosed cancer in women. In 2020, an estimated 2,261,419 new cases were diagnosed in women worldwide. Therefore, there is a need to understand the processes that can help us better treat this disease. In recent years, research in the fight against cancer has often been based on two treatment modalities. One of them is the use of protein kinase inhibitors, which have been instrumental in the development of new therapeutic strategies. Another crucial route is the use of immunotherapy, which has been touted as a great promise for cancer treatment. Protein kinase alterations can interfere with the effectiveness of other treatments, such as immunotherapy. In this review, we will analyze the role played by protein kinase alterations in breast cancer and their possible impact on the effectiveness of the response to immunotherapy treatments.

Citing Articles

Advances in pyrazolo[1,5-]pyrimidines: synthesis and their role as protein kinase inhibitors in cancer treatment.

Iorkula T, Jude-Kelly Osayawe O, Odogwu D, Ganiyu L, Faderin E, Awoyemi R RSC Adv. 2025; 15(5):3756-3828.

PMID: 39911541 PMC: 11795850. DOI: 10.1039/d4ra07556k.

References

Garrido-Castro A, Lin N, Polyak K . Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. Cancer Discov. 2019; 9(2):176-198. PMC: 6387871. DOI: 10.1158/2159-8290.CD-18-1177. View

Dai M, Feng Y, Chen S, Masuda N, Yau T, Chen S . Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with.... Breast Cancer Res Treat. 2021; 189(3):665-676. PMC: 8505315. DOI: 10.1007/s10549-021-06313-5. View

Anselmo A, Cobb M . Protein kinase function and glutathionylation. Biochem J. 2004; 381(Pt 3):e1-2. PMC: 1133907. DOI: 10.1042/BJ20040873. View

Emens L . Breast Cancer Immunotherapy: Facts and Hopes. Clin Cancer Res. 2017; 24(3):511-520. PMC: 5796849. DOI: 10.1158/1078-0432.CCR-16-3001. View

Sugden M, Holness M . Therapeutic potential of the mammalian pyruvate dehydrogenase kinases in the prevention of hyperglycaemia. Curr Drug Targets Immune Endocr Metabol Disord. 2002; 2(2):151-65. View

Kohama T, Olivera A, Edsall L, Nagiec M, Dickson R, Spiegel S . Molecular cloning and functional characterization of murine sphingosine kinase. J Biol Chem. 1998; 273(37):23722-8. DOI: 10.1074/jbc.273.37.23722. View

Whittaker S, Mallinger A, Workman P, Clarke P . Inhibitors of cyclin-dependent kinases as cancer therapeutics. Pharmacol Ther. 2017; 173:83-105. PMC: 6141011. DOI: 10.1016/j.pharmthera.2017.02.008. View

Boulay A, Rudloff J, Ye J, Zumstein-Mecker S, OReilly T, Evans D . Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res. 2005; 11(14):5319-28. DOI: 10.1158/1078-0432.CCR-04-2402. View

Gudi R, Kedishvili N, Zhao Y, Popov K . Diversity of the pyruvate dehydrogenase kinase gene family in humans. J Biol Chem. 1995; 270(48):28989-94. DOI: 10.1074/jbc.270.48.28989. View

10.

Lane H, Nigg E . Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes. J Cell Biol. 1996; 135(6 Pt 2):1701-13. PMC: 2133970. DOI: 10.1083/jcb.135.6.1701. View

11.

Brittle A, Nanba Y, Ito T, Ohkura H . Concerted action of Aurora B, Polo and NHK-1 kinases in centromere-specific histone 2A phosphorylation. Exp Cell Res. 2007; 313(13):2780-5. PMC: 2131725. DOI: 10.1016/j.yexcr.2007.04.038. View

12.

Rader J, Russell M, Hart L, Nakazawa M, Belcastro L, Martinez D . Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 2013; 19(22):6173-82. PMC: 3844928. DOI: 10.1158/1078-0432.CCR-13-1675. View

13.

Manning G, Whyte D, Martinez R, Hunter T, Sudarsanam S . The protein kinase complement of the human genome. Science. 2002; 298(5600):1912-34. DOI: 10.1126/science.1075762. View

14.

Topalian S, Drake C, Pardoll D . Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015; 27(4):450-61. PMC: 4400238. DOI: 10.1016/j.ccell.2015.03.001. View

15.

Ponde N, Aftimos P, Piccart M . Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review. Curr Treat Options Oncol. 2019; 20(5):37. DOI: 10.1007/s11864-019-0633-6. View

16.

Matsuda N, Wang X, Lim B, Krishnamurthy S, Alvarez R, Willey J . Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer. JAMA Oncol. 2018; 4(9):1207-1213. PMC: 6143003. DOI: 10.1001/jamaoncol.2018.1436. View

17.

Nakada T, Masuda T, Naito H, Yoshida M, Ashida S, Morita K . Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads. Bioorg Med Chem Lett. 2016; 26(6):1542-1545. DOI: 10.1016/j.bmcl.2016.02.020. View

18.

Zhang Y, Sicinska E, Czaplinski J, Remillard S, Moss S, Wang Y . Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivo. Mol Cancer Ther. 2014; 13(9):2184-93. DOI: 10.1158/1535-7163.MCT-14-0387. View

19.

Knecht R, Elez R, Oechler M, Solbach C, von Ilberg C, Strebhardt K . Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck. Cancer Res. 1999; 59(12):2794-7. View

20.

Li X, Yang C, Wan H, Zhang G, Feng J, Zhang L . Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer. Eur J Pharm Sci. 2017; 110:51-61. DOI: 10.1016/j.ejps.2017.01.021. View